Clinical trial · Interventional
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT03989414CI-TRIAL-00083096active not recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bortezomib | Drug | Bortezomib | ALIAS |
| Carfilzomib | Drug | Carfilzomib | ALIAS |
| CC-92480 | Drug | — | UNRESOLVED |
| Daratumumab | Drug | Daratumumab | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Elotuzumab | Drug | Elotuzumab | ALIAS |
| Isatuximab | Drug | Isatuximab | ALIAS |
Design
Arms and outcomes
Arms (15)
- type
- EXPERIMENTAL
- label
- Cohort A: CC-92480 with bortezomib and dexamethasone
- interventionNames
- Drug: CC-92480
- Drug: Bortezomib
- Drug: Dexamethasone
- type
- EXPERIMENTAL
- label
- Cohort C: CC-92480 with carfilzomib and dexamethasone
- interventionNames
- Drug: CC-92480
- Drug: Dexamethasone
- Drug: Carfilzomib
- type
- EXPERIMENTAL
- label
- Cohort H: CC-92480 with elotuzumab and dexamethasone
- interventionNames
- Drug: CC-92480
- Drug: Dexamethasone
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply: * Documented diagnosis of multiple myeloma (MM) and measurable disease * Documented disease progression during or after their last antimyeloma regimen * Achieved a response (minimal response \[MR\] or better) to at least 1 prior treatment regimen Exclusion Criteria: * Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis * Known central nervous system (CNS) involvement with myeloma * Received immunosuppressive medication within the last 14 days of initiating study treatment * Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment Other protocol-defined inclusion/exclusion criteria apply
References
Publications (0)
Data not yet available
No reference posted for this study.